Trial Profile
A multicenter randomized, double-blind, controlled study of NGX-4010 [capsaicin] for the treatment of postherpetic neuralgia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2011
Price :
$35
*
At a glance
- Drugs Capsaicin (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors NeurogesX
- 19 Dec 2008 Based on the results of this trial and one other, the FDA has accepted a NDA for review, reported by NeurogenesX. The brand name Qutenza is awaiting approval.
- 04 Mar 2008 Status changed from in progress to completed.
- 18 Apr 2007 Status changed from recruiting to in progress